GlassScriptPhysician profile
Daniel F Kaminsky
NPI 1710952858
$385.93
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $18.29 · 2022: $96.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $149.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.05 | 2019-2020 | |
| Davol INC. | $65.33 | 2022 | |
| Covidien LP | $34.91 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $30.96 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.47 | 2019 | |
| Therapeuticsmd, INC. | $12.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kaminsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.